Pacira BioSciences Inc (NAS:PCRX)
$ 16.81 -0.7 (-4%) Market Cap: 776.17 Mil Enterprise Value: 998.18 Mil PE Ratio: 0 PB Ratio: 1.03 GF Score: 72/100

Pacira Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 08:00PM GMT
Release Date Price: $61.23 (+2.00%)
Christopher Z. Neyor
JPMorgan Chase & Co, Research Division - Analyst

Good morning, everyone. I'm Chris here from the biopharma team at JPMorgan. It's my pleasure to be introducing Pacira BioSciences. From the company, we have CEO, David Stack. (Operator Instructions) With that, I'll hand it over to Dave. Happy New Year, and thanks for joining us.

David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO

Thank you, Christopher, and thank you to JPMorgan for the opportunity to spend a few minutes with you this afternoon. Any other disclosures can be found on the Pacira website. So Pacira has developed a portfolio of unique, safe, best-in-class products, which act along the patient's neural pathway to treat postsurgical pain, acute and chronic arthritis pain, spasticity as well additional unmet medical needs. As you can see on the slide, we have very large target addressable market opportunities with all of our products.

We believe that this unique portfolio allows us the opportunity to sell this suite of products to the same target audiences.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot